NO20074336L - 2-fenylindoler som prostaglandin D2 reseptorantagonister - Google Patents

2-fenylindoler som prostaglandin D2 reseptorantagonister

Info

Publication number
NO20074336L
NO20074336L NO20074336A NO20074336A NO20074336L NO 20074336 L NO20074336 L NO 20074336L NO 20074336 A NO20074336 A NO 20074336A NO 20074336 A NO20074336 A NO 20074336A NO 20074336 L NO20074336 L NO 20074336L
Authority
NO
Norway
Prior art keywords
bronchitis
pharmaceutically acceptable
xvi
formula
disorders
Prior art date
Application number
NO20074336A
Other languages
English (en)
Norwegian (no)
Inventor
Hans-Jochen Lang
Kenneth J Bordeau
Keith John Harris
Rose M Mathew
Stephen J Shimshock
Thaddeus R Neduzak
Sharon Jackson
Zhaoxia Yang
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20074336L publication Critical patent/NO20074336L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20074336A 2005-01-26 2007-08-24 2-fenylindoler som prostaglandin D2 reseptorantagonister NO20074336L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64730705P 2005-01-26 2005-01-26
PCT/US2006/002736 WO2006081343A1 (en) 2005-01-26 2006-01-25 2-phenyl-indoles as prostaglandin d2 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20074336L true NO20074336L (no) 2007-10-23

Family

ID=36282872

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074336A NO20074336L (no) 2005-01-26 2007-08-24 2-fenylindoler som prostaglandin D2 reseptorantagonister

Country Status (25)

Country Link
US (1) US20070265278A1 (enExample)
EP (1) EP1844011A1 (enExample)
JP (1) JP2008528606A (enExample)
KR (1) KR20070110277A (enExample)
CN (1) CN101146770A (enExample)
AR (1) AR054726A1 (enExample)
AU (1) AU2006209213A1 (enExample)
BR (1) BRPI0607079A2 (enExample)
CA (1) CA2595728A1 (enExample)
CR (1) CR9214A (enExample)
DO (1) DOP2006000016A (enExample)
GT (1) GT200600030A (enExample)
IL (1) IL184816A0 (enExample)
MA (1) MA29259B1 (enExample)
MX (1) MX2007008277A (enExample)
NO (1) NO20074336L (enExample)
PA (1) PA8661201A1 (enExample)
PE (1) PE20060878A1 (enExample)
RU (1) RU2007132166A (enExample)
SG (1) SG158918A1 (enExample)
TN (1) TNSN07251A1 (enExample)
TW (1) TW200639151A (enExample)
UY (1) UY29346A1 (enExample)
WO (1) WO2006081343A1 (enExample)
ZA (1) ZA200705449B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066628B1 (en) * 2006-07-25 2010-10-20 Sanofi-Aventis 2-phenyl-indoles as prostaglandin d2 receptor antagonists
CN101500996B (zh) 2006-08-07 2012-07-04 埃科特莱茵药品有限公司 (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物
WO2008061006A1 (en) * 2006-11-10 2008-05-22 Wyeth Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use
WO2009061730A2 (en) * 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
WO2012046653A1 (ja) * 2010-10-06 2012-04-12 株式会社クレハ アミン系化合物とその用途
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2548863A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
AR088204A1 (es) * 2011-09-29 2014-05-14 Shionogi & Co Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina
US9255090B2 (en) 2011-12-21 2016-02-09 Actelion Pharmaceuticals Ltd. Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP6168520B2 (ja) * 2013-09-17 2017-07-26 国立大学法人 千葉大学 インドール化合物、dpプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びdpプロスタノイド受容体アンタゴニストの使用。
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
RU2016140708A (ru) 2014-03-18 2018-04-18 Идорсиа Фармасьютиклз Лтд Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN113173877B (zh) * 2020-10-30 2023-10-27 江西师范大学 吲哚乙酰基亚氨基砜系列化合物及其制备方法
CN115925606B (zh) * 2023-01-05 2023-10-13 宁夏医科大学 一种5-(3-(磺酰胺基)苯基)-1h-吡咯-2-羧酸衍生物及其制备方法和应用
CN117599052A (zh) * 2023-07-25 2024-02-27 温州医科大学附属眼视光医院 Ptgds的抑制剂在制备治疗白内障药物上的应用
US12220411B1 (en) 2023-07-25 2025-02-11 The Eye Hospital Of Wenzhou Medical University Application of PTGDS inhibitor in preparation of drug for treating cataracts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950701317A (ko) * 1992-05-08 1995-03-23 오오쓰까 아끼히꼬 인돌 유도체(Indole Derivative)
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
JP2004024655A (ja) * 2002-06-27 2004-01-29 Aruze Corp 遊技機
JPWO2004078719A1 (ja) * 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EA200700243A1 (ru) * 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Also Published As

Publication number Publication date
IL184816A0 (en) 2007-12-03
TNSN07251A1 (en) 2008-12-31
GT200600030A (es) 2006-09-27
PA8661201A1 (es) 2006-09-08
US20070265278A1 (en) 2007-11-15
MX2007008277A (es) 2007-09-07
TW200639151A (en) 2006-11-16
AU2006209213A1 (en) 2006-08-03
KR20070110277A (ko) 2007-11-16
UY29346A1 (es) 2006-08-31
CN101146770A (zh) 2008-03-19
ZA200705449B (en) 2009-01-28
BRPI0607079A2 (pt) 2009-08-04
AR054726A1 (es) 2007-07-11
DOP2006000016A (es) 2006-07-31
MA29259B1 (fr) 2008-02-01
JP2008528606A (ja) 2008-07-31
RU2007132166A (ru) 2009-03-10
EP1844011A1 (en) 2007-10-17
CR9214A (es) 2007-11-23
WO2006081343A1 (en) 2006-08-03
PE20060878A1 (es) 2006-10-18
CA2595728A1 (en) 2006-08-03
SG158918A1 (en) 2010-02-26

Similar Documents

Publication Publication Date Title
NO20074336L (no) 2-fenylindoler som prostaglandin D2 reseptorantagonister
NO20072440L (no) 2,6-substituert-4-monosubstituertamino-pyrimidin som prostaglanding D2 reseptor antagonister
NO20084291L (no) 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister
TNSN08515A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
TNSN08131A1 (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
BR0109050A (pt) Derivados de indol, processo para prepapação e uso dos mesmos
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
EA200701268A1 (ru) Новые гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений
NO20054206L (no) Bifenylderivater
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20043894L (no) Karboksysyreforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
NO20080457L (no) Kjemiske forbindelser
NO20073436L (no) Nye heterosykliske forbindelser nyttige for behandling av inflammatoriske og allergiske forstyrrelser
NO20070076L (no) Nye indazolkarboksamider og deres anvendelse
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
NO20061207L (no) Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel
UA95303C2 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application